For the Fifth Straight Year Hologic Will Ring the Opening Bell at NASDAQ Ceremony Marking the Start of Breast Cancer Awareness Month
Rob Cascella, Hologic CEO and President, to Stress the Importance of Empowering Women to Take Care of Their Health

BEDFORD, Mass., Sept. 29, 2010 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that Rob Cascella, Hologic's President and Chief Executive Officer, will preside over the NASDAQ Stock Exchange Opening Bell Ceremony marking the start of Breast Cancer Awareness Month. The event is scheduled to begin at 9:15 a.m. (ET) on October 1, 2010.

Mr. Cascella will speak to the importance of empowering women to make their health a priority in order to reduce the number of women impacted by treatable diseases, such as breast cancer. "When you help a woman, you help a family. When you help a family, you help a community," Mr. Cascella notes. "Yet many women take care of others in their family, often missing important tests to keep themselves healthy. In breast cancer detection, there is no disagreement that early and accurate diagnosis of breast cancer is the key to improving clinical outcomes. In many cases, digital mammography can identify an abnormal breast mass as much as two years before it can be detected by touch."

Hologic takes its role as the leader in breast health very seriously. Hologic's digital mammography systems and workstations are leading technologies in breast cancer screening and diagnosis. Over the past several years, Hologic has been diligently working on new breast cancer screening and diagnosis technologies, most notably the development of breast tomosynthesis - fast, high-quality 3-D imaging of the breast.

If a suspicious lesion is detected, Hologic biopsy systems provide clinicians with easier and more effective access to those lesions. Should cancer be detected in its early stages, many women are candidates for Hologic's targeted radiation therapy, a unique and welcomed clinical option and a patient-friendly alternative for women that qualify. A recent acquisition, Sentinelle Medical, brings Hologic MRI breast coil and an integrated auxiliary table engineered to optimize patient comfort and diagnostic accuracy unlike ever before.

The Hologic Promise to Me initiative, first announced at the NASDAQ Opening Bell Ceremony for Breast Cancer Awareness Month in 2009, is aimed at increasing awareness of the importance of breast and cervical cancer screening and osteoporosis assessment, as well as empowering women to take ownership of their health, starting with scheduling an annual mammogram, bone density or annual gynecologic exam. Through the website, Hologic is further showing its support of women who are unable to afford screening by helping to fund mammograms, cervical cancer screening and bone density screening.

This is the fifth consecutive year that Hologic has been asked to participate in this special event to commemorate National Breast Cancer Awareness Month. In addition 2010 is Hologic's 20th anniversary year of being listed on the NASDAQ stock exchange.

The ceremony is aired live on and on the NASDAQ MarketSite Tower on Times Square in New York with closed captioning. For those that miss the live telecast, a video of the Opening Ceremony will be archived for a year on the NASDAQ site.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit

Hologic, Promise to Me and Sentinelle Medical are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of digital mammography, cervical cancer screening, and bone density assessment. There can be no assurance that these systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effects of the use of these systems can only be determined on a case-by-case basis
depending on the particular circumstances of the procedure and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.


Deborah R. Gordon
Vice President, Investor Relations
Hologic, Inc.
Tel: 781.999.7716

Olga Karagiannis
Corporate Marketing
Hologic, Inc. 
Tel: 781.761.7069